Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market by Product Type (DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine, by Age Group (Adult and Pediatric), and by End User (Hospitals, Clinics, and Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-18
- Report ID: 18198
- Pages: 193
-
Format:
The global diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% during the forecast period.
Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough) provide an impactful boost to the market growth. Approximately 86 % of infants worldwide (116.3 million children) received 3 doses of diphtheria-tetanus-pertussis 3 (DTP3) vaccine during 2018, shielding them from infectious diseases that may cause severe illness and disability, or could even be fatal. .
In 2017, the global demand for all D&T containing vaccines was estimated at around 945 million doses. Self-procuring countries represent almost half of the global demand for DTP vaccines. The WHO has recommended a life course of six doses of diphtheria and tetanus containing vaccines throughout the world. Thus, established firms are currently devoting almost 5% of their total R&D expenditure in vaccine development. Since last decade, biotech firms have emerged as a new force in the area of early stage product development and applied vaccine research. Players operating in the DTP vaccines market are mostly focused on establishing a strong network with dealers and their distributors. Players are partnering with other vaccine manufacturing companies to enhance their product portfolio as well as to expand their global reach. Vaccine development technology has witnessed a revolutionary growth, and has led to the expansion of innovative and new diagnostic technologies with various advancements in therapeutic applications.
The report classifies the global DTP vaccines market based on products, age group, end users, and region. By product, it is categorized into a DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is divided into adult and pediatric. By end users, it is categorized into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global DTP Vaccine market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Product Type
o DTaP
o TD
o Tdap
By Age Group
o Adult
o Pediatric
By End User
o Hospitals
o Clinics
o Vaccination Centers
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Rest of Europe
o Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
o LAMEA
Brazil
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
AJ Vaccines
Bionet-Asia
GlaxoSmithKline plc (GSK)
Johnson & Johnson
Massbiologics
Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
Merck & Co., Inc.
Panacea Biotec Ltd.
Sanofi
Serum Institute of India Pvt. Ltd
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top player positioning, 2019
3.3.Porters five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in initiatives by pharma companies to enhance vaccine R&D
3.4.1.2.Growth in awareness among people about the advantages of DTP vaccines
3.4.2.Restraints
3.4.2.1.Inadequate access to vaccines in under developed countries
3.4.2.2.High cost of vaccine development
3.4.3.Opportunities
3.4.3.1.Innovative vaccine technologies
CHAPTER 4:DTP VACCINES MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.DTaP Vaccines
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.TD Vaccines
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Tdap Vaccines
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:DTP VACCINES MARKET, BY AGE GROUP
5.1.Overview
5.1.1.Market size and forecast
5.2.Adults
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Pediatrics
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:DTP VACCINES MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Clinics
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Vaccination Centers
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:DTAP VACCINES MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by product
7.2.3.Market size and forecast, by age group
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. market size and forecast, by product
7.2.5.2.U.S. market size and forecast, by age group
7.2.6.Market size and forecast, by end users
7.2.6.1.Canada market size and forecast, by product
7.2.6.2.Canada market size and forecast, by age group
7.2.7.Market size and forecast, by end users
7.2.7.1.Mexico market size and forecast, by product
7.2.7.2.Mexico market size and forecast, by age group
7.2.8.Market size and forecast, by end users
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by product
7.3.3.Market size and forecast, by age group
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany market size and forecast, by product
7.3.5.2.Germany market size and forecast, by age group
7.3.6.Market size and forecast, by end users
7.3.6.1.France market size and forecast, by product
7.3.6.2.France market size and forecast, by age group
7.3.7.Market size and forecast, by end users
7.3.7.1.UK market size and forecast, by product
7.3.7.2.UK market size and forecast, by age group
7.3.8.Market size and forecast, by end users
7.3.8.1.Italy market size and forecast, by product
7.3.8.2.Italy market size and forecast, by age group
7.3.9.Market size and forecast, by end users
7.3.9.1.Rest of Europe market size and forecast, by product
7.3.9.2.Rest of Europe market size and forecast, by age group
7.3.10.Market size and forecast, by end users
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by product
7.4.3.Market size and forecast, by age group
7.4.4.Market size and forecast, by end users
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by product
7.4.5.2.Japan market size and forecast, by age group
7.4.6.Market size and forecast, by end users
7.4.6.1.China market size and forecast, by product
7.4.6.2.China market size and forecast, by age group
7.4.7.Market size and forecast, by end users
7.4.7.1.Australiamarket size and forecast, by product
7.4.7.2.Australia market size and forecast, by age group
7.4.8.Market size and forecast, by end users
7.4.8.1.India market size and forecast, by product
7.4.8.2.India market size and forecast, by age group
7.4.9.Market size and forecast, by end users
7.4.9.1.Rest of Asia Pacificmarket size and forecast, by product
7.4.9.2.Rest of Asia Pacific market size and forecast, by age group
7.4.10.Market size and forecast, by end users
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by product
7.5.3.Market size and forecast, by age group
7.5.4.Market size and forecast, by end users
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil market size and forecast, by product
7.5.5.2.Brazil market size and forecast, by age group
7.5.6.Market size and forecast, by end users
7.5.6.1.South Africa market size and forecast, by product
7.5.6.2.South Africa market size and forecast, by age group
7.5.7.Market size and forecast, by end users
7.5.7.1.Rest of LAMEA market size and forecast, by product
7.5.7.2.Rest of LAMEA market size and forecast, by age group
7.5.8.Market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.AJ VACCINES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.2.BIONET-ASIA
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.3.GLAXOSMITHKLINE PLC (GSK)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.JOHNSON & JOHNSON
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.MASSBIOLOGICS
8.5.1.Company overview
8.5.2.Company snapshot1
8.5.3.Product portfolio
8.6.MEIJI HOLDINGS CO., LTD. (KM BIOLOGICS CO., LTD.)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.MERCK & CO., INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.PANACEA BIOTEC LTD.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SANOFI
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.SERUM INSTITUTE OF INDIA PVT. LTD
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
